Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRD-Adapted Chemotherapy Duration in Follicular Lymphoma
NCT04934930Phase 2Unknown
- Sponsor
- Meir Medical Center
- Start
- Jan 2020
- Primary completion
- Aug 2025
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of bendamustine, obinutuzumab in follicular lymphoma (FL), sponsored by Meir Medical Center. Status: unknown.
02
Drugs
bendamustineobinutuzumab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT04934930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04934930.